AKT1 and cancer: For example, lipophilic antipsychotic drugs and others that can inhibit the major mechanism of resistance of the target therapy, such as PI3K-AKT-mTOR and STAT3, [188] can be tested with a wide range of target therapies and cancers (Supplementary Table S2).